📋 Key Information Summary
- Dyspepsia is defined as chronic or recurrent pain or discomfort centred in the upper abdomen, affecting approximately 30–40% of Australian adults annually, and accounting for a significant proportion of GP consultations.
- Always differentiate dyspepsia from cardiac pain — epigastric discomfort may represent acute coronary syndrome; perform an ECG and cardiac risk assessment when there is diagnostic uncertainty.
- Identify alarm features (weight loss, unintentional >5% in 6 months; unexplained iron-deficiency anaemia; persistent vomiting; dysphagia; GI bleeding; progressive symptoms) and age ≥60 years as indications for prompt endoscopy (OGD).
- Review medications — NSAIDs, aspirin, corticosteroids, bisphosphonates, SSRIs, anticoagulants — and counsel regarding alcohol cessation, smoking cessation, and weight management as first-line lifestyle interventions.
- Noninvasive H. pylori testing with urea breath test (UBT) or stool antigen test (SAT) is recommended for all patients <60 years without alarm features; serology alone is insufficient for active infection diagnosis.
- If H. pylori is detected, treat with a guideline-based eradication regimen — first-line: PPI + amoxicillin 1 g BD + clarithromycin 500 BD for 14 days; second-line or bismuth quadruple therapy for treatment failure.
- Confirm H. pylori eradication at ≥4 weeks after completing treatment and ≥2 weeks off PPI using UBT or SAT — do not rely on repeat endoscopy biopsy alone.
- For low-risk patients <60 years without alarm features: offer a 4–8 week empiric PPI trial (e.g., pantoprazole 40 mg or omeprazole 20 mg once daily) before considering referral or endoscopy.
- Patients ≥60 years with new-onset dyspepsia should proceed directly to endoscopy — the incidence of upper GI malignancy rises significantly after age 60 in the Australian population.
- Refer for endoscopy if symptoms persist or relapse despite confirmed H. pylori eradication and an adequate PPI trial, or if alarm features develop at any age.
- Aboriginal and Torres Strait Islander peoples have higher H. pylori prevalence, higher rates of gastric cancer presenting at younger ages, and reduced access to endoscopy in remote communities — lower the threshold for investigation and referral.
Introduction & Australian Epidemiology
Dyspepsia encompasses a spectrum of upper gastrointestinal symptoms including epigastric pain, burning, postprandial fullness, early satiation, bloating, and nausea. It is one of the most common presentations in Australian general practice, accounting for up to 5% of all GP encounters and is the most frequent reason for gastroenterology referral.
In Australia, community-based surveys estimate that 30–40% of adults experience dyspeptic symptoms in any given year, though only a minority seek medical attention. The annual prevalence of functional (non-ulcer) dyspepsia is approximately 15–20%, while peptic ulcer disease affects 5–10% of the population at some point in their lives. Gastro-oesophageal reflux disease (GORD) overlaps significantly and may co-exist.
The economic burden is substantial. Dyspepsia-related consultations, endoscopies, proton-pump inhibitor (PPI) prescriptions, and hospital admissions cost the Australian healthcare system an estimated .5–2 billion annually. PPIs remain among the most prescribed PBS-listed medications, with >20 million prescriptions dispensed per year nationally.
Key Australian Epidemiological Data
| Metric | Data |
|---|---|
| Community prevalence of dyspepsia | 30–40% per year |
| Functional (non-ulcer) dyspepsia | ~15–20% of adults |
| H. pylori seroprevalence (general population) | ~15–20% (declining) |
| H. pylori seroprevalence (ATSI communities) | ~60–80% in remote communities |
| Annual PPI prescriptions (PBS) | >20 million |
| Gastric cancer incidence (Australia) | ~2,300 new cases/year; mortality ~1,100/year |
Inequity in outcomes: Aboriginal and Torres Strait Islander Australians are diagnosed with gastric cancer at a younger age, present with more advanced disease, and have 1.5–2× the mortality rate compared with non-Indigenous Australians (AIHW 2023).
Initial Assessment & Alarm Features
The initial evaluation of a patient presenting with dyspepsia or epigastric pain requires a systematic approach to (1) exclude cardiac causes, (2) identify modifiable risk factors and offending medications, and (3) detect alarm features that mandate urgent investigation.
Step 1: Exclude Cardiac Pain
Critical safety step: Epigastric or upper abdominal discomfort may represent acute coronary syndrome (ACS), particularly inferior myocardial infarction. In any patient with cardiovascular risk factors (age, smoking, diabetes, hypertension, dyslipidaemia, family history), perform a 12-lead ECG and consider troponin measurement. Do not attribute symptoms to dyspepsia until cardiac causes are reasonably excluded.
1
Cardiac Assessment
ECG, troponin if indicated. Consider ACS especially in patients >40 years with risk factors. Pleuritic, exertional, or radiating pain to jaw/arm warrants emergency assessment.
2
Medication Review
NSAIDs (including OTC ibuprofen, naproxen), aspirin, corticosteroids, bisphosphonates, SSRIs/SNRIs, anticoagulants, potassium supplements, iron tablets, antibiotics.
3
Lifestyle Factors
Alcohol intake (≥14 standard drinks/week increases risk), smoking status, caffeine, obesity (BMI ≥30), dietary triggers, stress and psychosocial factors.
4
Alarm Feature Screen
Systematically enquire about each alarm feature below. Presence of any feature mandates urgent endoscopy referral.
Alarm Features Requiring Urgent Endoscopy
Any one alarm feature = direct endoscopy. Do not offer an empiric PPI trial or noninvasive H. pylori testing as an alternative — these patients require tissue diagnosis.
| Alarm Feature | Clinical Significance | Action |
|---|---|---|
| Unintentional weight loss (>5% body weight in 6 months) | Suggests malignancy or severe organic disease | Urgent OGD within 2 weeks |
| Progressive dysphagia | Oesophageal or gastric cardia malignancy; peptic stricture | Urgent OGD within 2 weeks |
| Persistent vomiting | Gastric outlet obstruction, malignancy, severe gastroparesis | Urgent OGD; consider CT abdomen |
| GI bleeding (haematemesis, melaena, positive faecal occult blood) | Peptic ulcer with active bleeding, malignancy, varices | Immediate OGD if haemodynamically significant |
| Iron-deficiency anaemia (unexplained) | Occult GI blood loss from ulcer, malignancy, coeliac disease | OGD + colonoscopy |
| Palpable abdominal mass | Advanced malignancy or large GIST | Urgent CT abdomen + OGD |
| Age ≥60 years with new-onset dyspepsia | Significantly increased risk of upper GI malignancy | Direct-to-endoscopy pathway |
Severity Assessment
Low Risk
Uncomplicated Dyspepsia
Age <60, no alarm features, intermittent or mild symptoms, no NSAID use, normal haemoglobin, no weight loss.
Setting: General practice — test-and-treat or empiric PPI
Moderate Risk
Persistent or Recurrent Dyspepsia
Age <60, no alarm features but symptoms >4 weeks, daily PPI use required, prior H. pylori treatment, or ongoing NSAID/aspirin use.
Setting: GP with early gastroenterology consideration
High Risk
Alarm Features or Age ≥60
Any alarm feature, new-onset dyspepsia age ≥60, haemodynamic instability, iron-deficiency anaemia, dysphagia, significant weight loss.
Setting: Urgent gastroenterology referral — direct endoscopy
Medication Review — Common Offending Agents
| Medication Class | Mechanism | Management |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib) | COX-1 inhibition → reduced mucosal prostaglandins, direct mucosal injury | Cease if possible; switch to paracetamol; if ongoing need, use lowest dose + co-prescribe PPI |
| Low-dose aspirin (100–300 mg) | Mucosal injury, impairs ulcer healing | Continues if cardiovascular indication; add PPI for gastroprotection |
| Corticosteroids (especially with NSAIDs) | Synergistic mucosal damage when combined with NSAIDs | Add PPI if concurrent NSAID use; avoid combination where possible |
| Bisphosphonates (alendronate, risedronate) | Oesophageal and gastric mucosal irritation | Review necessity; ensure correct administration technique |
| SSRIs / SNRIs | Increased GI bleeding risk (serotonin-mediated platelet effects) | Consider PPI co-prescription if concurrent antiplatelet/anticoagulant |
Noninvasive H. pylori Testing & Treatment
Test-and-Treat Strategy
For patients <60 years with dyspepsia and no alarm features, the recommended approach in Australian guidelines is the test-and-treat strategy: perform a noninvasive test for Helicobacter pylori and treat if positive, rather than proceeding directly to endoscopy. This strategy is cost-effective, reduces unnecessary endoscopies by approximately 30–40%, and achieves symptom resolution in 20–30% of dyspeptic patients.
Do not use serology (IgG) alone to guide treatment. Serology cannot distinguish active from past infection and has a positive predictive value of only ~70% in low-prevalence populations. Use urea breath test (UBT) or stool antigen test (SAT) for active infection detection. Serology may have a role in specific scenarios (recent PPI use, active GI bleeding, gastric atrophy) where UBT/SAT may yield false negatives.
Noninvasive Diagnostic Tests
✓ Widely Available
¹³C Urea Breath Test (UBT)
Sensitivity 95–97%, specificity 95–98%. Gold standard noninvasive test. Requires fasting ≥4 hours and cessation of PPI ≥2 weeks and antibiotics ≥4 weeks prior. MBS Item 12342 (approximate). Available in capital cities and major regional centres.
✓ Widely Available
H. pylori Stool Antigen Test (SAT) — Monoclonal EIA
Sensitivity 94–97%, specificity 95–97%. Can be performed while on PPI (slightly reduced sensitivity). Preferred in paediatric patients and where UBT unavailable. MBS-rebatable in selected contexts.
✓ Available
H. pylori IgG Serology
Sensitivity 85–95%, specificity 70–85%. Does NOT indicate active infection — remains positive for months to years after eradication. Use only when UBT/SAT are unavailable or contraindicated. Not recommended for test-of-cure.
Pre-Test Requirements
Stop PPI ≥2 weeks and antibiotics ≥4 weeks before UBT or SAT to avoid false-negative results. H2-receptor antagonists should be stopped ≥2 days before UBT. If the patient cannot safely cease PPI (e.g., severe GORD with stricture), use stool antigen testing which is less affected by concurrent acid suppression.
H. pylori Eradication Regimens
First-Line Therapy — Standard Triple Therapy (14 days)
Omeprazole (Losec®)
Multiple generics · Proton-pump inhibitor
Adult dose
20 mg PO BD (before meals)
Duration
14 days
Renal adjustment
No adjustment required
Hepatic adjustment
Consider dose reduction in severe hepatic impairment
PBS status
✔ PBS General Benefit
Amoxicillin
Amoxil® · Generic · Penicillin antibiotic
Adult dose
1 g PO BD
Paediatric dose
25–50 mg/kg/day divided BD (max 1 g per dose)
Duration
14 days
Renal adjustment
eGFR 10–30: max 500 mg TDS; eGFR <10: 500 mg BD
PBS status
✔ PBS General Benefit
Clarithromycin (Klacid®)
Klacid® · Generic · Macrolide antibiotic
Adult dose
500 mg PO BD
Duration
14 days
Renal adjustment
eGFR <30: reduce to 250 mg BD or use extended-release 500 mg once daily
Hepatic adjustment
Caution in severe hepatic impairment; monitor LFTs
PBS status
✔ PBS General Benefit
Australian clarithromycin resistance: Clarithromycin resistance in H. pylori in Australia has risen to approximately 10–20% in urban populations. In regions with known high resistance or in patients who have previously received macrolides (e.g., for respiratory infections), consider bismuth quadruple therapy as first-line or request culture with susceptibility testing. Indigenous and remote communities may have different resistance profiles — consult local microbiology data.
Second-Line Therapy — Bismuth Quadruple Therapy (14 days)
For patients who fail first-line triple therapy, or in areas of high clarithromycin resistance, bismuth quadruple therapy is the recommended second-line regimen.
Bismuth Subsalicylate / Subcitrate
De-Nol® · Colloidal bismuth subcitrate
Adult dose
120 mg (elemental bismuth) PO QID or 240 mg BD
Duration
14 days
PBS status
⚠ Authority Required
Metronidazole (Flagyl®)
Flagyl® · Generic · Nitroimidazole antibiotic
Adult dose
400 mg PO TDS (in bismuth quadruple regimen)
Duration
14 days
Renal adjustment
No adjustment; active metabolites accumulate — reduce frequency in severe impairment
PBS status
✔ PBS General Benefit
Tetracycline
Achromycin® · Generic · Tetracycline antibiotic
Adult dose
500 mg PO QID
Duration
14 days
Renal adjustment
Avoid in severe renal impairment (accumulation)
PBS status
✔ PBS General Benefit
Confirming Eradication — Test of Cure
Confirmation of eradication is mandatory. Perform UBT or stool antigen test at ≥4 weeks after completing eradication therapy and ≥2 weeks after stopping PPI. Treatment failure rates with first-line triple therapy are 15–25% in Australia. Do not use serology — it remains positive for months after successful eradication.
If first-line therapy fails, options include:
- Bismuth quadruple therapy (as above) — preferred second-line
- PPI + amoxicillin 1 g BD + levofloxacin 500 mg daily + bismuth — third-line option; local fluoroquinolone resistance data should guide use
- Referral for culture-guided therapy — consider in patients with ≥2 eradication failures; available at select reference laboratories (e.g., Royal Melbourne Hospital Microbiology, Westmead Hospital)
Empiric PPI Trial
For low-risk patients <60 years without alarm features, an empiric proton-pump inhibitor trial is a reasonable initial management strategy, either after a negative H. pylori test or as a first-line approach if testing is not immediately available. This approach is endorsed by the Australian Therapeutic Guidelines and the Gastroenterological Society of Australia (GESA).
When to Use Empiric PPI
- Age <60 years
- No alarm features (see alarm feature table above)
- H. pylori testing negative or test-and-treat completed
- Predominantly epigastric pain/burning (suggestive of functional dyspepsia or mild peptic ulcer disease)
- NSAID-related dyspepsia (after NSAID cessation or with ongoing NSAID use + gastroprotection)
PPI Dosing for Empiric Trial
Pantoprazole (Somac®)
Somac® · Generic · Proton-pump inhibitor
Adult dose
40 mg PO once daily, 30 minutes before breakfast
Duration
4–8 weeks (trial), then review
Renal adjustment
No adjustment required
Hepatic adjustment
Max 20 mg/day in severe cirrhosis
PBS status
✔ PBS General Benefit
Omeprazole (Losec®)
Losec® · Generic · Proton-pump inhibitor
Adult dose
20 mg PO once daily, 30 minutes before breakfast
Duration
4–8 weeks (trial), then review
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit
Esomeprazole (Nexium®)
Nexium® · Generic · Proton-pump inhibitor (S-enantiomer)
Adult dose
20 mg PO once daily for dyspepsia; 40 mg for erosive oesophagitis
Duration
4–8 weeks (trial), then step down or cease
Renal adjustment
No adjustment required
PBS status
✔ PBS General Benefit
PPI Trial Response Assessment
1
Complete 4–8 Week Trial
Take PPI 30 minutes before breakfast. Ensure adherence. Avoid concurrent alcohol, late-night eating, and trigger foods.
2
Assess Response at 4–8 Weeks
Complete symptom resolution → step down to lowest effective dose or attempt cessation. Partial response → continue to 8 weeks and reassess. No response → refer for endoscopy.
3
Step-Down or Cessation
If asymptomatic, reduce to lowest effective dose (e.g., pantoprazole 20 mg) or trial cessation. Relapse upon stopping may indicate the need for ongoing therapy or further investigation.
Avoid long-term PPI use without review. Ongoing PPI therapy beyond 8 weeks should be reassessed at least every 6–12 months. Long-term PPI use (>1 year) is associated with increased risk of Clostridioides difficile infection, hypomagnesaemia, vitamin B12 deficiency, osteoporotic fractures, and community-acquired pneumonia (absolute risk remains low). The benefits typically outweigh risks for clear indications (GORD, Barrett's oesophagus, Zollinger-Ellison syndrome).
Adjunctive and Lifestyle Measures
- Weight loss if BMI ≥25 — even 5–10% reduction improves symptoms
- Smoking cessation — reduces ulcer recurrence and improves mucosal healing
- Alcohol reduction — aim for <10 standard drinks/week; avoid binge drinking
- Dietary modifications — avoid late-night eating, large meals, known trigger foods (spicy, fatty, citrus, caffeine, chocolate)
- Elevate head of bed if nocturnal reflux symptoms
- Stress management — psychological comorbidity (anxiety, depression) is common in functional dyspepsia; consider CBT, low-dose TCAs (amitriptyline 10–25 mg nocte) if refractory
When to Refer for Endoscopy
Upper gastrointestinal endoscopy (oesophagogastroduodenoscopy, OGD) is the definitive investigation for dyspepsia and epigastric pain when indicated. In Australia, OGD is widely available through public and private gastroenterology services, with typical wait times of 2–4 weeks for urgent referrals and 4–12 weeks for routine referrals in the public system.
Indications for Endoscopy — Summary
| Indication | Urgency | Timeframe |
|---|---|---|
| Any alarm feature (weight loss, dysphagia, bleeding, anaemia, vomiting, mass) | Urgent | Within 2 weeks |
| New-onset dyspepsia age ≥60 years | Urgent | Within 2–4 weeks |
| Symptoms persist/relapse after confirmed H. pylori eradication + adequate PPI trial | Semi-urgent | Within 4–6 weeks |
| Failure to respond to 8-week empiric PPI trial | Semi-urgent | Within 4–8 weeks |
| Recurrent dyspepsia requiring repeated courses of PPI (>2 per year) | Routine | Within 8–12 weeks |
| Patient preference / diagnostic uncertainty | Routine | Within 8–12 weeks |
What Endoscopy Achieves
- Visualisation: Oesophagus, stomach, and duodenum — identifies erosive oesophagitis, peptic ulcers, malignancy, Barrett's oesophagus, gastric polyps, and other structural pathology
- Biopsy: CLO test (rapid urease test) for H. pylori at endoscopy; histopathological assessment for H. pylori, intestinal metaplasia, dysplasia, and malignancy
- Therapeutic intervention: Haemostasis for bleeding ulcers, dilation of strictures, endoscopic mucosal resection for early neoplasia
Pathway Algorithm
1
Exclude Cardiac Pain
ECG, troponin if indicated. If cardiac cause suspected → cardiology pathway.
2
Check Alarm Features + Age
Alarm features present OR age ≥60 → direct endoscopy pathway (skip to step 5).
3
H. pylori Test-and-Treat
UBT or SAT. If positive → 14-day eradication → confirm cure at 4 weeks. If negative → step 4.
4
Empiric PPI Trial (4–8 Weeks)
Pantoprazole 40 mg or omeprazole 20 mg daily. Lifestyle measures. Response → step-down. No response → step 5.
5
Endoscopy (OGD)
Biopsies for H. pylori, histology. Treat based on findings. If normal → functional dyspepsia diagnosis.
Functional dyspepsia accounts for up to 60–70% of dyspepsia cases with normal endoscopy findings. Diagnosis is by Rome IV criteria: one or more of bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning, with no structural disease on investigation. Management includes PPI trial, prokinetics, low-dose tricyclic antidepressants (amitriptyline 10–25 mg nocte), and psychological therapies.
Functional Dyspepsia — Second-Line Pharmacotherapy
Amitriptyline
Endep® · Generic · Tricyclic antidepressant (low-dose)
Adult dose
10 mg nocte, titrate to 25–50 mg nocte over 4–6 weeks
Duration
8–12 weeks minimum; reassess at 3 months
Renal adjustment
No specific adjustment; use with caution
PBS status
✔ PBS General Benefit (for depression indication; may require authority for functional dyspepsia)
Domperidone (Motilium®)
Motilium® · Generic · Prokinetic / dopamine antagonist
Adult dose
10 mg PO TDS, 15–30 minutes before meals
Duration
4–8 weeks, reassess efficacy
Renal adjustment
eGFR <30: reduce dose frequency to BD
PBS status
✔ PBS General Benefit
Domperidone safety: Associated with QT prolongation and serious cardiac arrhythmias (including sudden cardiac death) — avoid in patients with QTc >470 ms, concurrent QT-prolonging drugs, significant cardiac disease, hepatic impairment, or age >60 years. ECG monitoring recommended before initiating therapy.
Special Populations
Pregnancy
Dyspepsia in pregnancy
Very common (40–80% of pregnancies). First-line: lifestyle measures (small frequent meals, avoid lying flat, elevate head of bed). Antacids (e.g., calcium carbonate/magnesium hydroxide — Mylanta®) are safe. If inadequate, ranitidine (withdrawn in Australia — use famotidine 20 mg BD as alternative H2RA) or omeprazole/pantoprazole (Category B3 — use if benefit outweighs risk).
H. pylori in pregnancy
Do NOT test or treat during pregnancy — eradication regimens are teratogenic (tetracycline, metronidazole). Defer testing and treatment to postpartum period. Bismuth is also contraindicated in pregnancy.
Endoscopy
If alarm features present, endoscopy can be performed with appropriate precautions (left lateral position, foetal monitoring). Discuss with gastroenterology and obstetrics. Second trimester is safest.
Paediatrics
Dyspepsia in children
Functional dyspepsia is most common cause in children >8 years (Rome IV criteria). Alarm features (weight loss, GI bleeding, persistent vomiting, family history of peptic ulcer/GI malignancy, unexplained anaemia) warrant paediatric gastroenterology referral and endoscopy.
H. pylori testing
UBT (preferred) or stool antigen test — use paediatric formulations. Do NOT use serology. Only test if there is a clinical indication (not as screening). Eradication: PPI + amoxicillin 25–50 mg/kg/day BD + clarithromycin 7.5 mg/kg BD for 14 days. Weight-based dosing essential.
PPI use
Omeprazole 0.7–1 mg/kg/day (max 20 mg) or lansoprazole 0.5–1 mg/kg/day (max 15 mg) for 4 weeks. Avoid long-term use without clear indication. Use weight-based dosing in children <20 kg.
Elderly (≥65 years)
Threshold for investigation
Direct-to-endoscopy for any new-onset dyspepsia ≥60 years (some guidelines use ≥55 for ATSI patients). Higher prevalence of malignancy, atypical presentations, and polypharmacy. Silent GI bleeding is more common — check FBE and iron studies routinely.
PPI safety in elderly
Increased risk of C. difficile infection, hypomagnesaemia, falls and fractures, B12 deficiency. Use lowest effective dose and duration. Review every 3–6 months. Avoid abrupt cessation (rebound acid hypersecretion) — step down gradually over 2–4 weeks.
Medication interactions
PPIs reduce absorption of clopidogrel (especially omeprazole — prefer pantoprazole if concurrent use required). Also reduce absorption of iron, calcium, magnesium, and certain antifungals. Review interactions with pharmacist.
Renal Impairment
PPIs in CKD
Pantoprazole preferred (no dose adjustment required). PPIs are associated with accelerated CKD progression (OR 1.2–1.3) and acute interstitial nephritis — monitor eGFR. Long-term PPI use in CKD increases risk of hypomagnesaemia — monitor magnesium levels every 6–12 months.
H. pylori eradication
Adjust amoxicillin dose (see drug card above). Tetracycline is relatively contraindicated in eGFR <30 due to accumulation. Consider bismuth quadruple therapy with adjusted dosing. Clarithromycin: reduce dose to 250 mg BD if eGFR <30.
Hepatic Impairment
PPIs in liver disease
PPIs are metabolised hepatically — Child-Pugh C cirrhosis: reduce dose by 50% (e.g., pantoprazole 20 mg daily). PPI use in cirrhosis is associated with increased risk of spontaneous bacterial peritonitis (SBP) — use only with clear indication and monitor.
Clarithromycin
Caution in severe hepatic impairment — monitor LFTs. Consider dose adjustment or alternative regimen. Avoid metronidazole in severe hepatic disease.
Immunocompromised
CMV and other opportunistic causes
In immunocompromised patients (HIV, transplant recipients, chemotherapy), consider CMV oesophagitis, HSV oesophagitis, candidiasis, and other opportunistic infections as causes of upper GI symptoms. Lower threshold for endoscopy with biopsy and viral cultures.
Drug interactions
Clarithromycin interacts with calcineurin inhibitors (tacrolimus, cyclosporine) and many antiretrovirals. Use amoxicillin + metronidazole regimen if macrolide interaction is a concern. Consult infectious disease specialist.
Aboriginal and Torres Strait Islander Health Considerations
📚 References
- 1. Gastroenterological Society of Australia (GESA). Clinical update: Dyspepsia and H. pylori. Sydney: GESA; 2023. Available at: gesa.org.au.
- 2. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049–1057.
- 3. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373(19):1853–1863.
- 4. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762.
- 5. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–239.
- 6. National Health and Medical Research Council (NHMRC). Clinical practice guideline: Evidence review for the investigation and management of dyspepsia. Canberra: NHMRC; 2020.
- 7. Australian Institute of Health and Welfare (AIHW). Cancer in Aboriginal & Torres Strait Islander people of Australia. Canberra: AIHW; 2023.
- 8. Holtmann G, Shah A, Morrison M. Pathophysiology of functional gastrointestinal disorders: a holistic overview. Dig Dis. 2017;35(Suppl 1):5–13.
- 9. Royal Australian College of General Practitioners (RACGP). Prescribing drugs of dependence in general practice: Part B — Benzodiazepines and PPIs. Melbourne: RACGP; 2022.
- 10. Menon S, Nightingale P, Trivedi S, et al. Systematic review and meta-analysis of H. pylori infection in Aboriginal Australians. Intern Med J. 2020;50(9):1045–1054.
- 11. Pharmaceutical Benefits Scheme (PBS). Australian Government Department of Health. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia; 2024.
- 12. Drossman DA, Hasler WL. Rome IV — Functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–1261.
- 13. Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295–1302.
- 14. RHDAustralia (ASHM). Recommendations for the clinical management of H. pylori in Aboriginal and Torres Strait Islander populations. Darwin: RHDAustralia; 2021.